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Abstract
Background:  EBV lytic cycle activators, such as phorbol esters, anti-immunoglobulin,
transforming growth factor β (TGFβ), sodium butyrate, induce apoptosis in EBV-negative but not
in EBV-positive Burkitt's lymphoma (BL) cells. To investigate the molecular mechanisms allowing
EBV-infected cells to be protected, we examined the expression of viral and cellular antiapoptotic
proteins as well as the activation of signal transduction pathways in BL-derived Raji cells exposed
to lytic cycle inducing agents.
Results: Our data show that, following EBV activation, the latent membrane protein 1 (LMP1) and
the cellular anti-apoptotic proteins MCL-1 and BCL-2 were quickly up-regulated and that Raji cells
remained viable even when exposed simultaneously to P(BU)2, sodium butyrate and TGFβ. We
report here that inhibition of p38 pathway, during EBV activation, led to a three fold increment of
apoptosis and largely prevented lytic gene expression.
Conclusion: These findings indicate that, during the switch from the latent to the lytic phase of
EBV infection, p38 MAPK phosphorylation plays a key role both for protecting the host cells from
apoptosis as well as for inducing viral reactivation. Because Raji cells are defective for late antigens
expression, we hypothesize that the increment of LMP1 gene expression in the early phases of EBV
lytic cycle might contribute to the survival of the EBV-positive cells.
Background
Epstein Barr Virus (EBV), the causative agent of infectious
mononucleosis, is associated with an increasing number
of malignancies of epithelial and lymphoid origin that
include Burkitt's lymphoma (BL), nasopharyngeal carci-
noma, Hodgkin's lymphoma and immunoblastic lym-
phomas in posttransplant and AIDS patients [1].
Following primary infection, EBV infects epithelial cells
where it undergoes lytic replication, and B cells, where it
usually maintains a latent state [2]. All EBV-associated
tumors have a predominantly latent pattern of viral gene
expression. Three types of latent programs have been char-
acterized depending on the differential expression of a
limited set of viral genes. These include six nuclear anti-
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gens (EBNA1, 2, 3A, 3B, 3C and LP) and three membrane-
associated proteins (LMP1, LMP2A and 2B) plus several
small RNA species (EBERs).
In vitro, EBV infection of peripheral B lymphocytes results
in their immortalization and continuous proliferation [3].
Among the latent proteins, LMP1 plays a prominent role
in the process of EBV-associated oncogenesis. This integral
membrane protein can cause transformation of rodent
fibroblasts and epithelial cells in vitro [4,5] and induce
development of B cell lymphoma or epidermal hyperpla-
sia in transgenic mice [6,7]. By functioning as constitu-
tively activated member of the tumor necrosis factor
receptor (TNFR) family, through the cytoplasmic carboxy
terminus LMP1 triggers several signaling pathways to alter
cell growth and survival [8,9]. This viral oncoprotein stim-
ulates NFkB, JNK, the JAK/STAT, PI3K/Akt, ERK1/2, and
p38 mitogen activated protein kinase (MAPK) signal
transduction cascades [10]; in addition, it regulates several
downstream genes including anti-apoptotic genes such as
bcl-2 [11,12], mcl-1 [13], A20 [14] and survivin [15].
Viral reactivation is initiated by the two immediate early
proteins BZLF1 (ZEBRA or Zta) and BRLF1 (Rta) [16,17]
that function as transcriptional activators of EBV early
genes [18-20].
In vitro, latency can be disrupted by a variety of different
agents such as phorbol esters, sodium butyrate, TGFβ,
anti-immunoglobulins (anti-IgG) and calcium iono-
phores [21-23].
It has been reported that all these compounds induce
apoptosis in EBV-negative cells but not in BZLF1-positive
cells that appeared to be protected. Moreover, the antiap-
optotic effect was prevented by treatment of the cells with
inhibitors of viral DNA synthesis, leading to the hypothe-
sis that a late EBV gene product might be responsible for
survival of EBV-positive cells exposed to lytic cycle induc-
ing compounds [24].
In this report we have further examined the connection
between EBV lytic cycle induction and survival of the host
cell aiming to detect viral gene products and/or signal
transduction pathways involved in the protective effect.
To focus on the early phases of EBV productive cycle, we
used Burkitt lymphoma-derived Raji cells that, because of
a deletion in EBV genome, support an abortive cycle, only
allowing immediate early (IE) and early (E) genes expres-
sion [25]. We have previously shown that treatment of
Raji cells with phorbol-12,13-dibutyrate (P(BU)2),
sodium butyrate and TGFβ, activates EBV lytic cycle in
more than 60% of the cell population [26]. We report
here that following EBV activation, LMP1 and bcl-2 were
promptly up-regulated and, despite the lack of viral late
products, Raji cells were protected from apoptosis. We
demonstrate that the suppression of p38 phosphorylation
by its specific inhibitor caused a three fold increment of
apoptosis. Furthermore, we found that inhibition of p38
signaling pathway largely prevented EBV lytic gene expres-
sion. These findings indicate that p38 MAPK plays a key
role both in EBV activation as well as in host cell survival.
In addition, the increment of LMP1 expression at the
onset of the lytic phase suggests that the latent viral onco-
gene might contribute to preserve cell viability in the early
stages of EBV productive cycle.
Results
Activators of EBV lytic cycle induce apoptosis in EBV-
negative Burkitt's lymphoma cells
EBV lytic cycle can be induced in Burkitt's lymphoma cells
by treatment with phorbol esthers, anti-immunoglobulin,
sodium butyrrate or TGFβ. Although each of these agents
cause apoptosis, it has been reported that lytic EBV gene
expression prevents the cells to undergo the programmed
cell death [24].
To further investigate the protective effect exerted by EBV
infection, we treated EBV-positive Raji and EBV-negative
Ramos and BL41cells with P(BU)2, sodium butyrate and
TGFβ, a combination of agents able to trigger, in the
former, EBV immediate early (IE) and early antigen (EA)
expression in more than 60% of the population [26]. In
the cells exposed to these compounds, we monitored
apoptosis by analyzing in a cytofluorimeter the sub-G1
events and by Western blotting the proteolytic cleavage of
poly(ADP-ribose) polymerase (PARP). Fig. 1A illustrates
the results of a representative experiment where the per-
centages of cells with a sub-G1 DNA content were meas-
ured in the samples collected after 24 and 48 hours of
incubation with EBV lytic cycle inducing agents. It appears
that the fraction of EBV-negative cells with an hypodip-
loid DNA content increased with the incubation time. In
particular, after 48 hour, about 50% of BL41 and 70% of
Ramos cells were found in the sub-G1 peak. In contrast,
treatment of EBV-positive Raji cells with P(BU)2, sodium
butyrate and TGFβ for the same lengths of time did not
significantly affect the percentage of the sub-G1 popula-
tion that remained at about 10% for the entire time of
treatment. Results similar to those shown in Fig. 1A were
obtained when apoptosis was detected by annexin V-FITC
binding to phosphatidylserine (data not shown).
In addition, Western blotting analysis of PARP cleavage
carried out on the lysates of cells treated as mentioned
above, is illustrated in the image of Fig. 1B. It appears that
the 89 KDa apoptotic form of the protein was generated
in EBV negative Ramos and BL41 cells after incubation
with the lytic cycle activators for 24 and 48 hours, respec-
tively. Conversely, only the full form of PARP wasMolecular Cancer 2009, 8:18 http://www.molecular-cancer.com/content/8/1/18
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observed in Raji cells even when exposed to P(BU)2,
sodium butyrate and TGFβ for up to 72 hours.
In order to confirm that the different apoptotic response
in Raji cells was related to EBV infection, we compared
apoptosis in EBV-positive and EBV-negative Akata cells,
after treatment with anti-IgG. Table 1 reports the results of
a representative experiment as percentages of apoptotic
cells (annexin V-positive) and apoptotic plus necrotic
(annexin V and propidiun iodide positive) cells measured
by flowcitometry at 0, 24 and 48 hours. It is evident that
at 24 hours, the fraction of apoptotic cells in the EBV-
infected population was about one fifth of that measured
in the absence of the virus, indicating that EBV protects
Akata cells from IgG cross-linking induced apoptosis. This
result was confirmed by the analysis of the values meas-
ured at 48 hours indicating that post-apoptotic processes
in the EBV-negative cellls resulted in a much larger incre-
ment of cells permeable to propidium iodide. Results sim-
ilar to those shown in the Table were obtained when EBV
lytic cycle induction was triggered by P(BU)2, sodium
butyrate and TGFβ.
Expression of viral and cellular antiapoptotic genes during 
EBV lytic cycle induction
Because EBV-positive Raji cells appeared to be protected
from apoptosis despite incubation with multiple EBV lytic
cycle inducing compounds, we next examined the levels
of expression of both viral as well as cellular antiapoptotic
genes. Among the viral genes, LMP1, BHRF1 and BALF1
have been reported to suppress apoptosis. However,
BALF1 is not expressed in Raji cells because comprised in
the genome deletion that accounts for the replication
defect in this strain [25]. Therefore, we analyzed LMP1
and BHRF1 expression in Raji cells collected at different
times after addition to the culture of EBV lytic cycle activa-
tors. Fig. 2A shows that the immediate early antigen
BZLF1 (34 KDa) is rapidly expressed after EBV induction
and high levels of the protein are detected in the samples
collected after 8 hours of incubation with the inducers.
Similarly, the levels of LMP1 protein (63 KDa) dramati-
cally increased after 8 hours of exposure of the cells to
P(BU)2, sodium butyrate and TGFβ and raised further,
Evaluation of apoptosis in BL cells during exposure to EBV lytic cycle inducing compounds Figure 1
Evaluation of apoptosis in BL cells during exposure to EBV lytic cycle inducing compounds. EBV-positive Raji (cir-
cles) and EBV-negative Ramos (squares) and BL41 (triangles) cells were treated with P(BU)2, sodium butyrate and TGF-β as 
described in the Methods. At the indicated times (hours), samples were collected and analyzed for (A) cytofluorimetric deter-
minations of sub-G1 events after PI staining or (B) immunodetection of native (113 KDa) and apoptotic (89 KDa) forms of 
PARP by Western blot. The results are representative of those obtained in at least three independent experiments.
Table 1: Evaluation of apoptosis in EBV-positive and EBV-
negative Akata cells treated with anti-IgG
T a Ann V b Ann V + PI c
Akata 0 4 5
EBV 24 10 12
positive 48 22 25
Akata 0 5 16
EBV 24 54 26
negative 48 8 75
a Time of exposure of the cells to anti-IgG
b AnnexinV-positive cells (%)
c Annexin V plus propidium iodide-positive cells (%)Molecular Cancer 2009, 8:18 http://www.molecular-cancer.com/content/8/1/18
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reaching at 48 hours values about 10 times higher than
those measured in latently-infected cells (time 0). Con-
versely, BHRF1 (17 KDa) was detectable only 24 hours
after the addition of the lytic cycle activators and its level
increased between 24 and 48 hours.
Because LMP1 induces the cellular anti-apoptotic genes
mcl-1 and bcl-2 [13], we examined their expression dur-
ing EBV lytic cycle activation. The levels of MCL-1 (43
KDa) largely increased in the samples collected at 8 and
24 hours but started to decline thereafter, confirming the
previously reported transient increment following LMP1
expression. In contrast, BCL-2 levels slightly raised during
the first 24 hours of incubation of the cells with the induc-
ers, but in the samples collected at 48 hours, the intensity
of the specific band (29 KDa) was about three times
higher than that measured in the untreated cells (time 0).
To further investigate the time-course and the regulation
of the expression of the viral and the cellular anti-apop-
totic genes, we measured mRNA levels by RT-PCR to
assess whether the up-regulation of LMP1, MCL-1 and
BCL-2 proteins was related to increased transcription of
the corresponding genes. As it appears from Fig. 2B, a
semi-quantitative evaluation of the transcripts indicates
that besides EBV lytic genes, also LMP1, Mcl-1 and Bcl-2
expression is regulated at the transcriptional level. How-
ever, while LMP1 mRNA levels increased concomitantly
with BZLF1 gene expression after 2 hours exposure of the
cells to EBV lytic cycle activators, BHRF1 transcripts
appeared only after 4 hours. Similar times of incubation
of the cells with the inducing agents were necessary to
detect a slight but consistent increment of mcl-1 and bcl-
2 mRNAs.
EBV activation and ROS production
Variations in the redox state play an important role in
modulating cell survival and apoptosis. Therefore, we
asked whether the different percentage of apoptotic cells
measured in Raji and Ramos exposed to EBV activating
compounds, was related to variations in the levels of reac-
tive oxygen species (ROS). To this end, Raji and Ramos
cells were incubated with P(BU)2, sodium butyrate and
TGFβ for up to 48 hours. Within this period of time, cell
samples were collected, subjected to an oxidation-sensi-
tive probe and analyzed by flowcitometry. Fig. 3A shows
that in Raji cells ROS production increased in the first four
hours, reached a plateau and augmented to a greater
extent between 24 and 48 hours. In contrast, in Ramos
cells ROS levels were lower, both at early as well as at late
times after the addition to the culture of the inducing
agents.
In particular, at 48 hours, the values measured in the EBV
negative cell line were about one third of those measured
in Raji cells. To further evaluate these results, we analyzed
the sub-G1 population in Raji and Ramos cells exposed to
the inducers for 48 hours, in the absence or in the pres-
ence of N-acetyl cysteine. The bargraph of Fig. 3B indicates
that a slightly higher percentage of apoptosis was meas-
ured in Raji cells when EBV lytic cycle was induced in the
presence of the antioxidant molecule. However, N-acetyl
cysteine was not able to reduce apoptosis in Ramos cells,
clearly confirming that cell death of EBV-negative cells
was not related to higher production of ROS.
Contribution of signal transduction pathways to 
protection of induced Raji cells from apoptosis
In order to assess the role played by different signal trans-
duction pathways in protecting induced Raji cells from
apoptosis, EBV induction was carried out during exposure
of the cells to specific inhibitors of the main signaling
molecules known to be activated during the latent and/or
the early phases of the lytic EBV infection. Therefore, Raji
cells were incubated with P(BU)2, sodium butyrate and
TGFβ for 48 hours in the presence of SB203580,
PD98059, SP600125 or Wortmanin, specific inhibitors of
p38 MAPK, ERK, JNK and PI3K, respectively or with Bay
117082, inhibitor of NFkB pathway. Thereafter, cells were
subjected to cell cycle analysis and the apoptosis meas-
ured as the sub-G1 fraction of the cell population. As it
Expression of viral and cellular antiapoptotic genes during  EBV lytic cycle activation Figure 2
Expression of viral and cellular antiapoptotic genes 
during EBV lytic cycle activation. (A) Raji cells were 
exposed to lytic cycle inducing agents as described in the 
Methods. At the indicated times (hours), (A) cell lysates were 
resolved by 10% acrylamide SDS-PAGE, blotted on mem-
brane and probed with specific antibodies; (B) purified RNA 
was reverse transcribed and cDNA amplified with the spe-
cific primers (see Methods).Molecular Cancer 2009, 8:18 http://www.molecular-cancer.com/content/8/1/18
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appears from Fig. 4A, after exposure for 48 hours to EBV
lytic cycle activators about 5% of Raji cells was character-
ized by a hypodiploid DNA content. This percentage did
not vary significantly when EBV induction was carried out
in the presence of agents that inhibit ERK, JNK, PI3K and
NFkB pathways. In contrast, the addition of SB203580 at
a concentration proved not to be toxic on latently-infected
cells, causes a three fold increment of apoptosis, indicat-
ing that p38MAPK pathway highly contributed to protect
EBV-positive Raji cells from apoptosis. To assess the spe-
cificity of p38 signaling cascade in the protective effect on
Raji cells, we verified the activation of the different path-
ways by analyzing the phosphorylation pattern of p38,
ERK and JNK, as well as NFkB activity, at different times
after exposure of the cells to the inducing agents. As
shown in Fig. 4B, the results of Western blots carried out
with specific antibodies for p38, ERK, JNK and for the
phosphorylated forms of the three MAPKs, indicate that
all of them were activated. In particular, phosphorylation
of both p38MAPK and ERK strongly increased at 1 hour
after induction of EBV lytic cycle; however, the levels of
phospho-p38 remained high up to six hours, while phos-
pho-ERK increment appeared to be transient. Moreover,
JNK activation occurred at later times (3 hours), but
increased thereafter. Experiments carried out to verify the
efficacy of p38 inhibitor showed that at the concentration
used, SB203580 largely suppressed p38 phosphorilation
without affecting JNK or ERK activation (data not shown).
In addition, NFkB-DNA binding activity analyzed by
EMSA (Fig. 4C) revealed an increment in the signal corre-
sponding to the specific complex indicating that induc-
tion of EBV lytic cycle led to prompt and persistent
activation of the transcription factor NFkB.
Inhibition of signal transduction pathways and EBV lytic 
cycle activation
Because p38 signaling cascade appeared to be involved in
the protection of EBV-positive cells from apoptosis when
exposed to lytic cycle inducing compounds, we asked
whether inhibition of this pathway could affect EBV lytic
cycle activation. To assess this point, after a 48 hours incu-
bation of Raji cells with P(BU)2, sodium butyrate and
TGFβ in the presence of either SB203580, PD98059,
SP600125, Wortmanin, or Bay 117082, cell samples were
fixed on slides and treated for immunofluorescence stain-
ing with antibodies recognizing EBV early antigens.
In the panel of Fig. 5A, the results of a representative
experiment are shown. The image in a) shows that after 48
hours incubation with lytic cycle inducers, FITC-labeled
antibodies detected EA in a large percentage of the cell
population as previously reported [26]. EA expression was
also detected when lytic cycle induction was carried out in
the presence of inhibitors of ERK, JNK, PI3K or NFkB
pathway (pictures c, d, e and f).
In contrast, FITC fluorescence signal was absent in the
samples of cells incubated with SB203580 (picture b),
indicating that activation of p38 pathway is essential for
induction of EBV lytic cycle. To further analyze this result,
we measured the expression of BZLF1 and BFRF1, an
immediate early and an early antigen, respectively, of EBV
lytic program. As it appears from Fig. 5B, after a 48 hours
treatment with the inducers in the presence of SB203580,
the levels of both BZLF1 and BFRF1 were dramatically
reduced as compared to those measured in the absence of
the p38 inhibitor.
Discussion
In this study we have reexamined the relationship
between cell survival and EBV lytic cycle to determine viral
factors and/or signal transduction pathways involved in
ROS production in Raji and Ramos cells exposed to EBV lytic  cycle activators Figure 3
ROS production in Raji and Ramos cells exposed to 
EBV lytic cycle activators. (A) Cells were treated with 
P(BU)2, sodium butyrate and TGFβ. At the indicated times, 
samples of Raji (triangles) and Ramos (squares) were incu-
bated with an oxidation-sensitive probe and the oxidized flu-
orescent derivative analyzed by flowcytometry; (B) cells 
exposed to EBV lytic cycle activators in the absence (open 
bars) or in the presence (filled bars) of N-acetyl cysteine for 
48 hours were fixed and PI stained for cytofluorymetric 
determination of sub-G1 events. Error bars are the means ± 
SD of three independent experiments.Molecular Cancer 2009, 8:18 http://www.molecular-cancer.com/content/8/1/18
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Contribution of signal transduction pathways to cell viability during exposure of Raji cells to EBV lytic cycle activators Figure 4
Contribution of signal transduction pathways to cell viability during exposure of Raji cells to EBV lytic cycle 
activators. (A) Cells were pretreated for 15 min with the specific inhibitors of p38 (SB), ERK (PD), JNK (SP), PI3K (W) or 
NFkB (Bay) and then exposed to P(BU)2, sodium butyrate and TGFβ as described in the Methods. After 48 hours, cells were 
fixed and PI stained for cytofluorymetric determination of sub-G1 events; (B) cells were incubated with P(BU)2, sodium 
butyrate and TGFβ. At the indicated times (hours), cell lysates were prepared and the phosphorylation pattern of p38, ERK 
and JNK evaluated by Western blot analysis with the specific antibodies for each protein and its phosphorylated (P-) form; (C) 
cells were treated as in B. At the indicated times, cell extracts were incubated with a consensus NFkB binding site oligonucle-
otide (oligo) to evaluate NFkB activity by EMSA (see Methods).Molecular Cancer 2009, 8:18 http://www.molecular-cancer.com/content/8/1/18
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the protection of EBV-infected cells from apoptosis during
viral reactivation. We attempted to investigate this issue in
Raji cells that, treated with multiple agents, support a mas-
sive induction of an abortive EBV lytic cycle [25,26] char-
acterized by the expression only of the viral IE and E
genes. We show here that in contrast to EBV-negative BL
cell lines, EBV-positive Raji and Akata cells do not die,
even after prolonged exposure to the activating agents.
These results confirm and strengthen what previously
observed; in addition, because late antigens are not
expressed in Raji cells, our data exclude the possibility that
a late viral product is involved in the protective effect.
ROS have been implicated in the regulation of several cel-
lular functions, including intracellular signaling, tran-
scription activation, proliferation, and apoptosis [27-29].
For what concerns apoptosis, ROS can act as a reactive sig-
nal, denature DNA and alter intracellular organelles [30-
32].
We asked whether treatment of the cells with EBV lytic
cycle activators would differently affect ROS levels in EBV-
positive and negative BL cells to account for survival or
apoptosis. Recently, it has been reported that in vitro EBV
infection is associated with ROS production [33]; further-
more, EBV-positive BL have been shown to express high
EBV activation in the presence of inhibitors of signal transduction pathways Figure 5
EBV activation in the presence of inhibitors of signal transduction pathways. Raji cells were treated as described in 
Fig. 4 A. (A) Fixed cells were stained for immunofluorescence analysis with FITC-labelled antibodies specific for EBV early anti-
gens: a) no inhibitor; b), c), d), e), f) plus inhibitor of p38, ERK, JNK, PI3K or NFkB, respectively; (B) Raji cells were exposed to 
EBV activators in the absence (I) or in the presence (I+SB) of p38 inhibitor. At 48 hours, cell extracts were resolved onto a 
10% acrylamide gel by SDS-PAGE, blotted and probed with BZLF1 or BFRF1 antibodies. Hybridization with GAPDH antibodies 
was used as loading control. Specific signal were visualized by ECL.Molecular Cancer 2009, 8:18 http://www.molecular-cancer.com/content/8/1/18
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levels of MAPK and ROS while EBV-negative BLs exhibit
activation of PI3-kinase, but do not have elevated levels of
ROS [34]. Our data show that upon exposure to lytic cycle
inducing compounds, ROS production remains higher in
the EBV-positive as compared with the EBV-negative cells;
in addition, pretreatment with N-acetyl cystein (a ROS
inhibitor) did not block cell death of EBV-negative BL
cells, further indicating that apoptosis occurring in these
cells is not related to ROS production.
We next looked for viral factors and signal transduction
pathways that could play a role in the protection of EBV-
positive cells from apoptosis upon induction of EBV lytic
cycle.
Many gamma herpesviruses appear to express their BCL-2
homologues early in the lytic replication cycle, raising the
possibility that herpesvirus BCL-2 proteins prolong cell
survival to allow production of greater numbers of prog-
eny. Here we show that EBV BCL-2 homologue BHRF1 is
expressed only 24 hours after addition of lytic cycle activa-
tors, while a dramatic increment of LMP1 is detectable as
soon as after 8 hours. Moreover, the transcriptional activa-
tion of LMP1 in the lytic cycle results in the up-regulation
of the MCL-1 and BCL-2 cellular anti-apoptotic proteins
as previously described to occur in LMP1-transfected B
lymphocytes [13].
The increment of LMP1 in the early phases of EBV lytic
cycle has been previously reported [35,36]. However, in
contrast to the knowledge of the roles during EBV latency,
little is known about the biological significance of LMP1
up-regulation during the lytic cycle of viral replication. It
has been reported that loss of LMP1 severely impairs the
release of viral particles [37]. Other studies have shown
that LMP1 expression inhibits EBV lytic cycle induction
and progress [38]. Furthermore, a number of reports indi-
cate that LMP1 expression levels directly affect the ability
to stimulate signaling and cell proliferation positively, or
to inhibit protein synthesis and induce cytostasis [39,40].
Far from being completely elucidated, it is conceivable
that LMP1 up-regulation during EBV lytic cycle induction
serves to prepare a suitable cell environment for virus rep-
lication by promoting cell survival or by triggering some
essential signaling pathways. In this respect, our prelimi-
nary results obtained in cells exposed to EBV lytic cycle
activators in the presence of LMP1-siRNA indicate that the
latter is able to prevent LMP1 up-regulation and increase
the percentage of apoptotic cells. Moreover, immunofluo-
rescence experiments carried out on Raji cells exposed to
EBV lytic cycle activators confirmed that BZLF1 and high
levels of LMP1 are co-expressed in the same cell (data not
shown).
We show here that the inhibition of p38 MAPK at the
onset of EBV lytic cycle, increases by three fold the per-
centage of apoptotic Raji cells indicating that p38 phos-
phorylation largely contributes to protect EBV-positive BL
cells during the early phases of EBV activation. It is well
known that p38 MAPK as well as NFkB signaling transduc-
tion cascades are triggered by LMP1 to inhibit apoptosis
and promote cell survival [10,41]. Our data indicate an
increment of NFkB activity upon induction of EBV lytic
phase of infection. However, evidence has been provided
showing that treatment of Kaposi's sarcoma-associated
herpesvirus (KSHV) or EBV latently-infected lymphocytes
with an NFkB inhibitor leads to virus reactivation, sug-
gesting that high NFkB activity levels contribute to main-
tenance of the viral latency state [42]. It can be
hypothesized that the apparent discrepancy between our
results and what was previously reported strictly depends
on the cellular context. In this respect, treatment of Raji
cells with an NFkB inhibitor did not lead to EBV reactiva-
tion in Raji cells (unpublished observations).
We also report that inhibition of p38 prevents EBV lytic
cycle induction in Raji cells indicating the prominent role
that this signaling pathway plays in the process of EBV
reactivation. Data have been provided demonstrating that
siRNA targeting p38MAPK blocks p38 phosphorylation
and BZLF1 expression induced by TPA in EBV-positive
epithelial cells [43]. Furthermore p38 inhibition pre-
vented efficient disruption of viral latency by surface IgG
crosslinking in Akata cells [44]. Our results, obtained in
Raji cells in which the virus is activated with three lytic
cycle inducing agents, confirm and extend the essential
involvement of p38 activation in the break of viral
latency. However, because Raji cells are exposed to multi-
ple agents, each one able to trigger BZLF1 expression, it is
likely the effector being downstream of BZLF1 activation.
The immediate early genes BZLF1 and BRLF1 activate one
another's transcription and together trans-activate EBV
early genes. They both induce phosphorylation of p38
kinase as well as JNK to activate the cellular transcription
factor ATF2 [44]. It has also been found that, in contrast
to BZLF1, the ability of BRLF1 expression vector to induce
lytic EBV infection is markedly reduced by inhibition of
either p38 or JNK pathways [44]. From our data it seems
conceivable that p38 inhibitor might prevent EBV activa-
tion by interfering with p 38-mediated transcription of
BZLF1 by BRLF1. However, the delayed phosphorylation
of JNK with respect to the other MAPKs and the evidence
that EBV activation occurs also in the presence of JNK
inhibitor, indicate that this signal transduction pathway is
not involved in the early phases of lytic infection in Raji
cells.Molecular Cancer 2009, 8:18 http://www.molecular-cancer.com/content/8/1/18
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Conclusion
In conclusion, we report here that at the onset of EBV lytic
cycle, p38 MAPK activation plays an important role both
for protecting EBV-infected Raji cells from apoptosis, as
well as for promoting EBV lytic gene expression. Our data
strongly suggest that the increment of LMP1 protein
occurring upon EBV reactivation may contribute in a rele-
vant way to both events. Studies are currently carried out
to test this hypothesis by elucidating the function of LMP1
up-regulation in the switch from latency to EBV lytic pro-
gram.
Methods
Cell culture and treatment with EBV lytic cycle activators
EBV-positive Raji and Akata and EBV-negative Ramos,
BL41 and Akata, are Burkitt's lymphoma (BL)-derived cell
lines. They were cultured in RPMI 1640 medium contain-
ing 5% fetal calf serum (FCS) and antibiotics, in a 5%
CO2 atmosphere and maintained at a cell density of 3.5 ×
105/ml.
Cells, at a density of 5 × 105 cells/ml, were incubated in
RPMI 1640/2,5% FCS with P(BU)2  (Sigma), sodium
butyrate (Sigma) and TGF-β2 (Genzyme, sp.act. 5 × 107
U/mg) at the final concentrations of 20 ng/ml, 2 mM and
0.04 ng/ml, respectively.
In addition, EBV-positive and EBV-negative Akata cells at
a density of 2 × 106/ml were incubated for 2 hours with
100 μg/ml of anti human IgG (Sigma) and subsequently
diluted to 106 cells/ml. At different times, cell samples
were collected and analyzed as described below. Cell via-
bility was assessed by trypan blue exclusion.
Cytofluorimetric analysis
The percentage of non viable cells was determined by
FACS analysis after DNA staining with propidium iodide
(PI). Cell samples were washed with phosphate buffer
saline (PBS) and centrifuged for 5 min at 300 × g. The cell
pellet was fixed for 1 h at 4°C with 70% ethanol, washed
with PBS, and treated for 1 hour with 100 μg/ml of PI and
100 μg/ml RNase. DNA content was assessed by using an
Epics Coulter XL flowcytometer. Apoptotic cells (pre-G1
peak) were considered as showing a DNA content less
than 2N. Alternatively, early apoptosis was evaluated by
annexin V-FITC apoptosis detection kit (Sigma) that
measures annexin V binding to phosphatidylserine in
conjunction with propidium iodide staining, according to
the accompaining procedure.
Western blot analysis
Cells (about 106) were collected and washed with PBS
before being lysed in Laemmli buffer. To detect phospho-
rylated proteins, cells were resuspended in lysis buffer
(0,1% NaN3, 1 mM CaCl2, 1 mM MgCl2, 150 mM NaCl,
0.5 μM aprotinin, 4 μM leupeptin, 2 mM PMSF, 10 mM
NaF, 10 mM iodoacetamide, 1 mM Na3VO4, 1% Triton-X
100 in PBS) and kept for 30 min on ice. Equal amounts of
proteins (70 μg), as determined by a modified Lowry
assay (RC DC protein assay, BioRad), were resolved on a
10% acrylamide gel by SDS-PAGE and transferred to
PVDF membrane. The blots were incubated with PBS/
0.1% Tween 20/5% non fat milk for 1 hour before being
probed in the same solution with the following primary
antibodies: anti LMP1 (1: 7500, PD Pharmigen), anti
BCL-2 (1: 200, Dako), anti PARP (1: 5000, Alexis), anti
MCL-1 (1: 200, Santa Cruz), anti BHRF1 (1: 20, kind gift
from Dr. Kremmer, GSF-Forschungszentrum, Munich,
Germany), anti p38 (1: 500, Santa Cruz), anti P-p38 (1:
500, Cell Signaling), anti ERK and anti P-ERK (both 1:
1000, Cell Signaling), anti JNK (1:1 000, Santa Cruz), anti
P-JNK (1: 500, Santa Cruz), anti BZLF1 (1: 100, Argene),
or anti BFRF1 (1: 1000, kindly provided by Dr. A. Farina,
Dept. of Experimental Medicine, Univ. of Rome
"Sapienza", Italy), for 1 hour at 25°C. The blots were fur-
ther incubated for one hour with horseradish peroxidase
conjugated anti-mouse or anti-rabbit (both 1: 5000,
Amersham) or anti rat (1: 10000, Jackson IR). The specific
signals were visualized by ECL detection kit (Amersham).
RT-PCR experiments
Total RNA was isolated from Raji cells as previously
described [45]. The specific primers for mcl-1, bcl-2,
LMP1 and GAPDH, the PCR conditions and the size of the
amplified sequences have been previously reported [45].
PCR products were loaded onto a 1.5% agarose gels con-
taining 0.5 μg/ml ethidium bromide and visualized under
UV light.
Production of Reactive Oxigen Species (ROS)
Aliquots (2.5 × 105) of untreated cells or cells incubated
with EBV lytic cycle inducing compounds in the absence
or in the presence of 2.5 mM N-acetyl cysteine, were col-
lected and washed three times in 5 mM HBSS buffer pH
7.4 before being incubated with 1 μM 5,6-carbossy-2',7'-
diclorohydro fluoresceine diacetate (DCFH-DA, Molecu-
lar Probes, Eugene, OR, USA) for 15' at room temperature.
ROS production was analyzed by flowcytometry (EPICS
Coulter-XL, FL, USA, excitation: 488 nm, emission: 530
nm) by measuring the oxidized fluorescent derivative
DCF [46]. The levels of ROS detected in untreated cells or
in H2O2 treated cells have been considered as basal level
and positive control, respectively, to determine ROS pro-
duction following EBV lytic cycle induction.
Inhibition of signal transduction pathways
Samples of Raji and Ramos cells at a density of 1 × 106/ml,
were incubated for 15' at 37°C, in the presence of 10 μM
SB203580 (SIGMA), 10 μM PD98059, 10 μM SP600125
or 1 μM Wortmanin (all from Calbiochem), specificMolecular Cancer 2009, 8:18 http://www.molecular-cancer.com/content/8/1/18
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inhibitors of p38 MAPK, ERK, JNK and PI3K, respectively,
or with 5 μM Bay 117082 (Sigma), inhibitor of NFkB.
Cells were then diluted with an equal volume of RPMI
1640 medium containing EBV lytic cycle inducing agents.
After 48 hours, cell samples were collected and analyzed
by Western blot, flowcytometry and fluorescence micros-
copy.
Electrophoretic Mobility Shift Assay (EMSA)
Whole cell extracts were obtained after lysis in a high salt
extraction buffer (50 mM Tris-HCl pH 7.5, 400 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1% Triton X100, 0.5% NP40,
10% glycerol, 2 mM DTT, 2 μM aprotinin, 2 μM leupep-
tin, 1 mM Na3VO4, 2 μM pepstatin, 1 mM PMSF). 20 μg
were incubated with 30 fmol of a DIG-labeled (DIG oligo-
nucleotide 3' end-labeling kit, Roche Applied Science) kB
DNA probe [47], in a binding buffer (20 mM Tris-HCl pH
7.5, 2 mM EDTA, 10% glycerol) containing 1 μg BSA, 0.5
μg poly d(I-C), for 20 min at room temperature. Com-
plexes were resolved by nondenaturing 4% polyacryla-
mide gel electrophoresis, transferred to nylon membrane
and detected by chemiluminescence (DIG luminescent
detection kit, Roche Applied Science).
Fluorescence microscopy
Treated cells were smeared on slide, fixed and permeabi-
lized with methanol:acetone (2:1) for 5 min at -20°C and
then stained with FITC-conjugated F6-Ester 2 antibodies
recognizing EBV early antigens (EA), as previously
described [48]. Slides were mounted with 50% glycerol in
PBS and analyzed with a Leica DM4000 fluorescence
microscope equipped with a FX 340 digital camera.
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